Matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic kidney disease and acute kidney injury: a systematic review of the literature
- PMID: 31641330
- PMCID: PMC6801125
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic kidney disease and acute kidney injury: a systematic review of the literature
Abstract
Introduction: Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in remodeling the extracellular matrix. Tissue inhibitors of metalloproteinases (TIMPs) are a family of four proteins that act to limit the degradative actions of MMPs. Chronic kidney disease (CKD) and acute kidney injury (AKI) are public health problems worldwide, the prevalence of which has been increasing. Recent concept considers MMPs and TIMPs as critical factors before the onset of microalbuminuria, as well as accelerating factors associated with the breakdown of the glomerular basement membrane, renal scarring, and fibrosis during the progression of kidney diseases. Here we reviewed studies of the expression of MMPs and TIMPs in humans, using as clinical samples serum, plasma, and urine, with a focus on their potential role as molecular markers in CKD and AKI, as non-invasive markers.
Material and methods: We used as data sources, studies at Medline database using combinations of the following keywords: CKD, AKI, MMP, TIMP, serum, plasma, and urine.
Results: Evidence suggests that MMPs/TIMPs could be potential targets for therapeutic intervention in kidney diseases; future studies should attempt to improve the diagnostic or prognostic power of these families.
Discussion: Considering published guides, such as biospecimen reporting for improved study quality (BRISQ), strengthening the reporting of observational studies in epidemiology (STROBE), an updated list of essential items for reporting diagnostic accuracy studies (STARD), transparent reporting of a multivariate prediction model for individual prognosis or diagnosis (TRIPOD), and on the studies reviewed here, we have adapted published recommendations and proposed other news in order to enhance the transparency and quality of MMPs/TIMPs research in CKD and AKI. This review reinforces the complexities of MMPs/TIMPs in the pathobiology of the kidney and the need for well-designed and transparent biomedical studies. HIPPOKRATIA 2018, 22(3): 99-104.
Keywords: Matrix metalloproteinases; acute kidney injury; chronic kidney disease; tissue inhibitors of metalloproteinases.
Copyright 2018, Hippokratio General Hospital of Thessaloniki.
Conflict of interest statement
Authors declare no conflict of interest.
Similar articles
-
Matrix Metalloproteinases in Kidney Disease: Role in Pathogenesis and Potential as a Therapeutic Target.Prog Mol Biol Transl Sci. 2017;148:31-65. doi: 10.1016/bs.pmbts.2017.03.001. Epub 2017 May 4. Prog Mol Biol Transl Sci. 2017. PMID: 28662825 Review.
-
Correlation of serum and urinary matrix metalloproteases/tissue inhibitors of metalloproteases with subclinical allograft fibrosis in renal transplantation.Transpl Immunol. 2014 Jan;30(1):1-6. doi: 10.1016/j.trim.2013.11.004. Epub 2013 Nov 27. Transpl Immunol. 2014. PMID: 24291496
-
Relationships between Circulating Matrix Metalloproteinases, Tissue Inhibitor TIMP-2, and Renal Function in Patients with Myocarditis.Kidney Blood Press Res. 2021;46(6):749-757. doi: 10.1159/000519594. Epub 2021 Nov 19. Kidney Blood Press Res. 2021. PMID: 34801997
-
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury After Massive Burns.Med Sci Monit. 2024 May 6;30:e943500. doi: 10.12659/MSM.943500. Med Sci Monit. 2024. PMID: 38706186 Free PMC article.
-
Role of Matrix Metalloproteinases in Degenerative Kidney Disorders.Curr Med Chem. 2018;25(15):1805-1816. doi: 10.2174/0929867325666171205143441. Curr Med Chem. 2018. PMID: 29210632 Review.
Cited by
-
Advances in kidney disease: pathogenesis and therapeutic targets.Front Med (Lausanne). 2025 Feb 14;12:1526090. doi: 10.3389/fmed.2025.1526090. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40027896 Free PMC article. Review.
-
Kidney Transplant Recipients with Acute Antibody-Mediated Rejection Show Altered Levels of Matrix Metalloproteinases and Their Inhibitors: Evaluation of Circulating MMP and TIMP Profiles.Int J Mol Sci. 2025 Jun 23;26(13):6011. doi: 10.3390/ijms26136011. Int J Mol Sci. 2025. PMID: 40649789 Free PMC article.
-
Delayed treatment with an autophagy inhibitor 3-MA alleviates the progression of hyperuricemic nephropathy.Cell Death Dis. 2020 Jun 17;11(6):467. doi: 10.1038/s41419-020-2673-z. Cell Death Dis. 2020. PMID: 32555189 Free PMC article.
-
The Utility of Novel Kidney Injury Biomarkers in Early Detection of CSA-AKI.Int J Mol Sci. 2022 Dec 14;23(24):15864. doi: 10.3390/ijms232415864. Int J Mol Sci. 2022. PMID: 36555506 Free PMC article.
-
The Effect of Immunosuppressive Drugs on MMPs Activity in The Walls of Blood Vessels - A Systematic Review.Int J Med Sci. 2021 Jan 30;18(6):1502-1509. doi: 10.7150/ijms.54423. eCollection 2021. Int J Med Sci. 2021. PMID: 33628108 Free PMC article.
References
-
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kindey Diseases. Kidney Int Suppl. 2013;3:1–150. Available at: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf, date accessed:31/05/2018. - PubMed
-
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1–138. Available at: https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-En..., date accessed: 31/05/2018.
-
- Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol. 2007;292:F905–F911. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous